The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the […]
Payers can face challenges in using appropriate management strategies close to launch. It’s difficult to have a complete picture of a therapy or device when manufacturers hesitate sharing certain information amid unclear FDA regulations. […]
As part of Precision Value & Health, we are excited to announce that we have been ranked #6 in MM&M magazine’s 2018 Agency Top 100 list. With a 10.6% increase in revenue from the previous year, we are continuing to add talent and services–partnering with pharmaceutical and life sciences companies to ensure patient access to life-changing therapies.
Lessons Learned from the Oncology Care Model Implementation: Maximizing the Value of Health Economics Evidence—presented by PHE Senior Economist and former Congressional Budget Office Deputy Assistant Director, Dr. James Baumgardner, and PHE Scientific Advisor, Dr. Wade Aubry, former Chief Medical Officer of Blue Shield of California. […]
For more information, or to learn how to change your cookies preferences, please click here.